Globus Medical EBITDA Margin 2010-2022 | GMED

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Globus Medical (GMED) over the last 10 years. The current EBITDA margin for Globus Medical as of June 30, 2022 is .
Globus Medical EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-06-30 $0.98B $0.26B 26.46%
2022-03-31 $0.96B $0.24B 24.74%
2021-12-31 $0.96B $0.25B 25.57%
2021-09-30 $0.94B $0.29B 30.29%
2021-06-30 $0.93B $0.28B 30.20%
2021-03-31 $0.83B $0.20B 24.73%
2020-12-31 $0.79B $0.18B 22.18%
2020-09-30 $0.77B $0.16B 21.22%
2020-06-30 $0.75B $0.15B 20.32%
2020-03-31 $0.79B $0.22B 27.33%
2019-12-31 $0.79B $0.22B 28.37%
2019-09-30 $0.77B $0.21B 27.79%
2019-06-30 $0.74B $0.21B 27.99%
2019-03-31 $0.72B $0.21B 28.57%
2018-12-31 $0.71B $0.21B 29.92%
2018-09-30 $0.69B $0.22B 31.21%
2018-06-30 $0.68B $0.21B 31.70%
2018-03-31 $0.65B $0.21B 32.11%
2017-12-31 $0.64B $0.21B 32.70%
2017-09-30 $0.61B $0.21B 33.82%
2017-06-30 $0.60B $0.21B 34.56%
2017-03-31 $0.58B $0.20B 34.94%
2016-12-31 $0.56B $0.20B 35.28%
2016-09-30 $0.56B $0.21B 36.94%
2016-06-30 $0.56B $0.21B 37.23%
2016-03-31 $0.55B $0.21B 37.07%
2015-12-31 $0.55B $0.20B 36.63%
2015-09-30 $0.53B $0.18B 34.40%
2015-06-30 $0.51B $0.18B 34.31%
2015-03-31 $0.49B $0.17B 34.48%
2014-12-31 $0.48B $0.16B 34.32%
2014-09-30 $0.46B $0.16B 33.62%
2014-06-30 $0.45B $0.15B 33.11%
2014-03-31 $0.44B $0.13B 28.89%
2013-12-31 $0.43B $0.12B 28.57%
2013-09-30 $0.42B $0.12B 28.57%
2013-06-30 $0.41B $0.12B 28.68%
2013-03-31 $0.40B $0.14B 34.01%
2012-12-31 $0.39B $0.13B 34.37%
2012-09-30 $0.37B $0.13B 33.96%
2012-06-30 $0.36B $0.13B 34.71%
2012-03-31 $0.35B $0.12B 34.20%
2011-12-31 $0.33B $0.11B 34.44%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $6.225B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.023B 21.80
Edwards Lifesciences (EW) United States $54.208B 38.35
Alcon (ALC) Switzerland $30.150B 25.53
STERIS (STE) Ireland $17.307B 21.50
Teleflex (TFX) United States $9.641B 15.36
Fresenius Medical Care AG KGaA (FMS) Germany $8.287B 7.64
Penumbra (PEN) United States $7.435B 891.96
Glaukos (GKOS) United States $2.693B 0.00
Integer Holdings (ITGR) United States $2.196B 17.17
Nevro (NVRO) United States $1.739B 0.00
Paragon 28 (FNA) United States $1.384B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.081B 16.55
Artivion (AORT) United States $0.519B 49.50